CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies
February 20, 2019 10:30 ET
|
Centre for the Commercialization of Antibodies and Biologics
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at...
CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies
August 21, 2018 08:30 ET
|
Centre for the Commercialization of Antibodies and Biologics
TORONTO, Aug. 21, 2018 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) and ImmunoBiochem Corporation have announced an agreement that will see CCAB...